Can Retatrutide Affect Menstruation?
Based on current evidence, there is no documented effect of retatrutide on menstruation, though this represents a significant knowledge gap as menstrual outcomes were not systematically assessed in clinical trials.
Current Evidence Status
The FDA drug label for retatrutide 1 does not mention menstrual effects or reproductive outcomes. The major phase 3 trial of retatrutide in type 2 diabetes 2 enrolled 296 women (55% of participants) but did not report menstrual outcomes as endpoints. Similarly, metabolomic studies of retatrutide 3 and cardiovascular/lipid analyses 4 made no mention of menstrual cycle changes.
Why This Matters Clinically
Mechanisms That Could Theoretically Affect Menstruation
Retatrutide causes substantial weight loss (11.5-15.3% body weight reduction at 40 weeks) 2, which can impact menstrual function through several pathways:
- Rapid weight loss can trigger functional hypothalamic amenorrhea (FHA) when energy availability becomes insufficient for normal reproductive function 5
- Energy deficit from reduced caloric intake may suppress GnRH drive, regardless of whether it results from dietary restriction or increased exercise 5
- Women experiencing significant weight changes should be monitored for menstrual pattern alterations, including cycle frequency, flow changes, and amenorrhea 5
What to Monitor in Clinical Practice
When prescribing retatrutide to women of reproductive age, assess:
- Baseline menstrual pattern: cycle frequency, duration, flow volume, presence of flooding or clots 5
- Weight trajectory: rapid weight loss (>1-2 kg/week) increases risk of menstrual disruption
- Energy intake: ensure adequate nutrition despite appetite suppression from GLP-1 agonist effects
- Stress and exercise patterns: multiple stressors may compound reproductive dysfunction 5
Red Flags Requiring Evaluation
If amenorrhea develops during retatrutide treatment, exclude:
- Pregnancy (always first priority)
- Galactorrhea, headache, vision changes (suggesting prolactinoma) 5
- Thyroid dysfunction symptoms 5
- Signs of androgen excess if PCOS is in differential 5
Comparison to Related Medications
Evidence from GLP-1 agonists in PCOS suggests these drug classes can actually improve menstrual regularity. Exenatide combined with metformin increased the ratio of actual to expected menses (0.90 vs 0.68, p<0.001) 6. However, this was in the context of PCOS treatment, not obesity management in women with regular cycles.
Clinical Recommendation Algorithm
For women with regular menses starting retatrutide:
- Document baseline menstrual pattern before initiating therapy
- Counsel about potential for menstrual changes with significant weight loss
- Monitor menstrual patterns at each follow-up visit
- If amenorrhea develops: rule out pregnancy, assess weight loss velocity, evaluate energy intake
- Consider slowing dose escalation if rapid weight loss coincides with menstrual disruption
Common pitfall: Assuming GI side effects are the only concern with retatrutide. The substantial metabolic changes 3 and weight reduction 2 create physiologic stress that may affect reproductive function, even though this wasn't captured in trial endpoints.
The absence of reported menstrual effects in trials 2 likely reflects lack of systematic assessment rather than true absence of effect, given that 55% of participants were women and the magnitude of weight loss achieved.